148 related articles for article (PubMed ID: 29416744)
1. Experimental evidence of good efficacy and reduced toxicity with peptide-doxorubicin to treat gastric cancer.
Zhang J; Yuan JP; Wang Q; Shao LH; Liu SP; Firestone RA; Hong YP; Li JG; Xin YC; Li Y
Oncotarget; 2018 Jan; 9(2):1957-1968. PubMed ID: 29416744
[TBL] [Abstract][Full Text] [Related]
2. Targeting therapy of hepatocellular carcinoma with doxorubicin prodrug PDOX increases anti-metastatic effect and reduces toxicity: a preclinical study.
Wang Q; Zhong YJ; Yuan JP; Shao LH; Zhang J; Tang L; Liu SP; Hong YP; Firestone RA; Li Y
J Transl Med; 2013 Aug; 11():192. PubMed ID: 23961994
[TBL] [Abstract][Full Text] [Related]
3. Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity.
Tang L; Duan R; Zhong YJ; Firestone RA; Hong YP; Li JG; Xin YC; Wu HL; Li Y
Mol Cancer; 2014 Mar; 13():44. PubMed ID: 24588871
[TBL] [Abstract][Full Text] [Related]
4. Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients.
Kawaguchi K; Igarashi K; Kiyuna T; Miyake K; Miyake M; Murakami T; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Singh AS; Unno M; Eilber FC; Hoffman RM
Cell Cycle; 2018; 17(5):627-633. PubMed ID: 29384032
[TBL] [Abstract][Full Text] [Related]
5. Anti-cancer effects of novel doxorubicin prodrug PDOX in MCF-7 breast cancer cells.
Zhang J; He L; Geng XF; Firestone RA; Hong YP; Li Y
J Huazhong Univ Sci Technolog Med Sci; 2014 Aug; 34(4):521-528. PubMed ID: 25135721
[TBL] [Abstract][Full Text] [Related]
6. Recombinant methioninase in combination with doxorubicin (DOX) overcomes first-line DOX resistance in a patient-derived orthotopic xenograft nude-mouse model of undifferentiated spindle-cell sarcoma.
Igarashi K; Kawaguchi K; Li S; Han Q; Tan Y; Murakami T; Kiyuna T; Miyake K; Miyake M; Singh AS; Eckardt MA; Nelson SD; Russell TA; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Singh SR; Eilber FC; Hoffman RM
Cancer Lett; 2018 Mar; 417():168-173. PubMed ID: 29306021
[TBL] [Abstract][Full Text] [Related]
7. High Efficacy of Pazopanib on an Undifferentiated Spindle-Cell Sarcoma Resistant to First-Line Therapy Is Identified With a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model.
Igarashi K; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Singh AS; Nelson SD; Dry SM; Li Y; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
J Cell Biochem; 2017 Sep; 118(9):2739-2743. PubMed ID: 28176365
[TBL] [Abstract][Full Text] [Related]
8. Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model.
Kiyuna T; Murakami T; Tome Y; Igarashi K; Kawaguchi K; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Russell TA; Singh SR; Kanaya F; Eilber FC; Hoffman RM
Tissue Cell; 2018 Aug; 53():30-36. PubMed ID: 30060824
[TBL] [Abstract][Full Text] [Related]
9. Effective molecular targeting of CDK4/6 and IGF-1R in a rare FUS-ERG fusion CDKN2A-deletion doxorubicin-resistant Ewing's sarcoma patient-derived orthotopic xenograft (PDOX) nude-mouse model.
Murakami T; Singh AS; Kiyuna T; Dry SM; Li Y; James AW; Igarashi K; Kawaguchi K; DeLong JC; Zhang Y; Hiroshima Y; Russell T; Eckardt MA; Yanagawa J; Federman N; Matsuyama R; Chishima T; Tanaka K; Bouvet M; Endo I; Eilber FC; Hoffman RM
Oncotarget; 2016 Jul; 7(30):47556-47564. PubMed ID: 27286459
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin arrests a doxorubicin-resistant PDGFRA-activated liposarcoma patient-derived orthotopic xenograft (PDOX) nude mouse model.
Kiyuna T; Tome Y; Murakami T; Kawaguchi K; Igarashi K; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Russell TA; Elliott I; Singh SR; Kanaya F; Eilber FC; Hoffman RM
BMC Cancer; 2018 Aug; 18(1):840. PubMed ID: 30126369
[TBL] [Abstract][Full Text] [Related]
11. Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Murakami T; Kiyuna T; Igarashi K; Kawaguchi K; Li Y; Singh AS; Dry SM; Eckardt MA; Hiroshima Y; Momiyama M; Matsuyama R; Chishima T; Endo I; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Jan; 119(1):967-972. PubMed ID: 28681998
[TBL] [Abstract][Full Text] [Related]
12. Growth of doxorubicin-resistant undifferentiated spindle-cell sarcoma PDOX is arrested by metabolic targeting with recombinant methioninase.
Igarashi K; Li S; Han Q; Tan Y; Kawaguchi K; Murakami T; Kiyuna T; Miyake K; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Apr; 119(4):3537-3544. PubMed ID: 29143983
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide targets and arrests a doxorubicin-resistant follicular dendritic-cell sarcoma patient-derived orthotopic xenograft mouse model.
Oshiro H; Tome Y; Kiyuna T; Miyake K; Kawaguchi K; Higuchi T; Miyake M; Zang Z; Razmjooei S; Barangi M; Wangsiricharoen S; Nelson SD; Li Y; Bouvet M; Singh SR; Kanaya F; Hoffman RM
Tissue Cell; 2019 Jun; 58():17-23. PubMed ID: 31133242
[TBL] [Abstract][Full Text] [Related]
14. Oral Recombinant Methioninase Combined with Caffeine and Doxorubicin Induced Regression of a Doxorubicin-resistant Synovial Sarcoma in a PDOX Mouse Model.
Higuchi T; Kawaguchi K; Miyake K; Han Q; Tan Y; Oshiro H; Sugisawa N; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Chawla SP; Singh AS; Eilber FC; Singh SR; Tsuchiya H; Hoffman RM
Anticancer Res; 2018 Oct; 38(10):5639-5644. PubMed ID: 30275182
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide regresses a doxorubicin-resistant undifferentiated spindle-cell sarcoma patient-derived orthotopic xenograft (PDOX): precision-oncology nude-mouse model matching the patient with effective therapy.
Igarashi K; Kawaguchi K; Kiyuna T; Miyake K; Miyake M; Li Y; Nelson SD; Dry SM; Singh AS; Elliott IA; Russell TA; Eckardt MA; Yamamoto N; Hayashi K; Kimura H; Miwa S; Tsuchiya H; Eilber FC; Hoffman RM
J Cell Biochem; 2018 Aug; 119(8):6598-6603. PubMed ID: 29737543
[TBL] [Abstract][Full Text] [Related]
16. Regorafenib regressed a doxorubicin-resistant Ewing's sarcoma in a patient-derived orthotopic xenograft (PDOX) nude mouse model.
Miyake K; Kiyuna T; Kawaguchi K; Higuchi T; Oshiro H; Zhang Z; Wangsiricharoen S; Razmjooei S; Li Y; Nelson SD; Murakami T; Hiroshima Y; Matsuyama R; Bouvet M; Chawla SP; Singh SR; Endo I; Hoffman RM
Cancer Chemother Pharmacol; 2019 May; 83(5):809-815. PubMed ID: 30758647
[TBL] [Abstract][Full Text] [Related]
17. The Combination of Cisplatinum and Doxorubicin Regressed Primary Osteosarcoma of the Breast in a PDOX Mouse Model.
Wu NF; Yamamoto J; Aoki Y; Masaki N; Samonte C; Wu J; Bouvet M; Hoffman RM
Anticancer Res; 2021 Oct; 41(10):4715-4718. PubMed ID: 34593419
[TBL] [Abstract][Full Text] [Related]
18. Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models.
Kawaguchi K; Igarashi K; Miyake K; Kiyuna T; Miyake M; Singh AS; Chmielowski B; Nelson SD; Russell TA; Dry SM; Li Y; Unno M; Singh SR; Eilber FC; Hoffman RM
J Drug Target; 2019 Feb; 27(2):211-216. PubMed ID: 30024282
[TBL] [Abstract][Full Text] [Related]
19. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model.
Oshiro H; Tome Y; Miyake K; Higuchi T; Sugisawa N; Kanaya F; Nishida K; Hoffman RM
Sci Rep; 2021 Apr; 11(1):8583. PubMed ID: 33883561
[TBL] [Abstract][Full Text] [Related]
20. Olaratumab combined with doxorubicin and ifosfamide overcomes individual doxorubicin and olaratumab resistance of an undifferentiated soft-tissue sarcoma in a PDOX mouse model.
Higuchi T; Miyake K; Sugisawa N; Oshiro H; Zhang Z; Razmjooei S; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Lett; 2019 Jun; 451():122-127. PubMed ID: 30867142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
